SUNLENCA® Was Studied In CAPELLA, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial (N=72)1
Oral SUNLENCA: 600 mg (2 x 300-mg tablets) on Day 1, 600 mg (2 x 300-mg tablets) on Day 2, 300 mg (1 x 300-mg tablet) on Day 8.
SC SUNLENCA: 927-mg (2 x 1.5 mL) subcutaneous injections on Day 15, followed by a maintenance dose of 927 mg (2 x 1.5 mL) every 6 months.
Important Safety Information
- Most common adverse reactions (incidence ≥3%, all grades) through Week 52 were injection site reactions (65%) and nausea (4%).
SUNLENCA was studied in a wide range of treatment-experienced patients with HIV-11
For illustrative purposes only. Not actual patient.